Clinical Trials
18 trialsNCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT00082706 2025-09-09
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06983210 2025-08-14
GRAPE
Nagoya University
Phase 2 Recruiting
NCT01326871 2024-06-25
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
Phase 1/2 Completed
NCT00942331 2023-10-16
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003376 2023-06-22
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003701 2023-06-15
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT00006111 2021-02-21
Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
UNICANCER
Phase 2 Completed
NCT02300610 2019-08-01
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01089088 2018-10-26
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
Phase 2 Completed
NCT01090466 2018-02-06
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Cardiff University
Phase 1/2 Completed
NCT01639521 2014-01-29
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Phase 2 Withdrawn
NCT00002684 2013-07-03
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00022191 2013-06-12
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00055835 2013-01-31
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
SWOG Cancer Research Network
Phase 2 Completed
NCT00080795 2012-10-22
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
M.D. Anderson Cancer Center
Phase 2 Completed